Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paul J. Turcott"'
Autor:
Daniel Kallin, Marit M. van Buuren, Jessica Kohler, Jonathan McGee, C.M. Nijenhuis, Joost H. van den Berg, Dewi Harjanto, Paul J. Turcott, Janani Sridar, Divya Lenkala, Brian C. McCarthy, Richard B. Gaynor, Michael D. Nelson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. NEO-STI
Autor:
Jonathan McGee, Divya Lenkala, Prerna Suri, Gabe S. Sonke, John B. A. G. Haanen, Marit M. van Buuren, Jessica Kohler, Christina M. Arieta, Richard B. Gaynor, C.M. Nijenhuis, Mark DeMario, Brian C. McCarthy, Maarje Rohaan, Susan Hannes, Dewi Harjanto, Daniel Kallin, Paul J. Turcott, Diana Velez, Shirisha Meda
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A212-A212
BackgroundNeoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. Here, we
Autor:
Jared L. Dietze, Daniel A. Rothenberg, Terri A. Addona, Antoine Boudot, Jessica Kohler, Jennifer G. Abelin, Vikram R. Juneja, Paul J. Turcott, Brandon P. Conn, Marit M. van Buuren, Scott P. Goulding, Christopher D. McGann, Richard B. Gaynor, John R. Srouji, Kendra C. Foley, Jae Won Choi, Michael S. Rooney, Divya Lenkala
Publikováno v:
Cell Reports Methods. 1:100084
Summary Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell res
Autor:
Vikram R. Juneja, Terri A. Addona, John Srouji, Jae Won Choi, Michael S. Rooney, Brandon P. Conn, Paul J. Turcott, Christopher D. McGann, Jennifer G. Abelin, Richard B. Gaynor, Antoine Boudot, Marit M. van Buuren, Scott P. Goulding, Jessica Kohler, Divya Lenkala, Daniel A. Rothenberg, Jared L. Dietze
Publikováno v:
Cancer Research. 80:PO-015
Response rates to immunotherapies in pancreatic ductal adenocarcinoma (PDAC) patients are low. However, cases with long-term survival have been correlated with both T cell infiltration and quality of neoantigens (i.e., epitopes from mutations present